Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 16/20 | 0.56 |
| ▸ | HRH1 | P35367 | 16/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966262 | 0.92 | SMN1; SMN2 (0.56) | HRH2HRH1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL10854255 | 0.87 | HRH2 (0.53) | HRH2HRH1POLBSMN1; SMN2HRH3 | |
| SCHEMBL27166403 | 0.85 | HRH2 (0.56) | HRH2HRH1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL9405372 | 0.83 | POLB (0.73) | HRH2HRH1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL30404652 | 0.83 | SMN1; SMN2 (0.56) | HRH2HRH1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL46979 | 0.83 | SMN1; SMN2 (0.56) | HRH2HRH1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL11182660 | 0.83 | HRH2 (0.52) | HRH2HRH1POLBSMN1; SMN2HRH3 | |
| SCHEMBL4199473 | 0.81 | SMN1; SMN2 (0.54) | HRH2HRH1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL5594524 | 0.80 | POLB (0.65) | HRH2HRH1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL14670199 | 0.80 | HRH2 (0.56) | HRH2HRH1POLBSMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |